Raymond James Financial Inc. Takes Position in CareDx, Inc (NASDAQ:CDNA)

Raymond James Financial Inc. purchased a new stake in CareDx, Inc (NASDAQ:CDNA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 172,559 shares of the company's stock, valued at approximately $3,694,000. Raymond James Financial Inc. owned about 0.32% of CareDx at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of CareDx by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 511,922 shares of the company's stock valued at $10,960,000 after acquiring an additional 12,442 shares during the period. Plato Investment Management Ltd raised its position in CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after purchasing an additional 1,370 shares during the last quarter. US Bancorp DE boosted its stake in CareDx by 907.5% during the 4th quarter. US Bancorp DE now owns 17,168 shares of the company's stock worth $368,000 after purchasing an additional 15,464 shares during the period. Bradley & Co. Private Wealth Management LLC purchased a new position in CareDx during the 4th quarter worth $269,000. Finally, Bank of New York Mellon Corp increased its stake in CareDx by 3.9% in the fourth quarter. Bank of New York Mellon Corp now owns 145,270 shares of the company's stock valued at $3,110,000 after purchasing an additional 5,502 shares during the period.

Analysts Set New Price Targets

A number of research firms recently issued reports on CDNA. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and decreased their price objective for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Stephens restated an "overweight" rating and set a $40.00 price target on shares of CareDx in a research note on Thursday, February 27th. Finally, HC Wainwright lowered their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $31.83.

Remove Ads

CareDx Stock Down 1.2 %

CDNA stock traded down $0.21 on Monday, reaching $17.75. 580,277 shares of the company's stock were exchanged, compared to its average volume of 845,828. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84. The stock has a fifty day moving average of $21.32 and a 200-day moving average of $23.52. The firm has a market cap of $983.81 million, a PE ratio of -6.57 and a beta of 1.95.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. The business had revenue of $86.58 million for the quarter, compared to analysts' expectations of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. On average, equities research analysts predict that CareDx, Inc will post -0.9 EPS for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.